Add to Favourites
To login click here
GRAIL, LLC, a healthcare company, has released data evaluating the Galleri multi-cancer early detection test’s ability to detect a cancer signal and predict the cancer signal origin in asymptomatic individuals in the real-world setting. The findings were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and support that the real-world performance of Galleri is consistent with previous large-scale clinical studies. Positive Galleri results with a cancer signal origin prediction were associated with a diagnosis of invasive cancer across multiple cancer types, including stage I and II cancers.
